A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis

Soheil Najafia Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Nahid Beladi Moghadamb Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of Medical Science, Tehran, IranCorrespondence[email protected] [email protected]

Payam Saadatc Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

Seyyedeh Masoomeh Noorbakhsha Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Anita Vali Mohammadid Shiraz Branch, Islamic Azad University, Shiraz, Iran

Ali Manouchehriniae Department of Clinical Neuroscience (CNS), Karolinska Institutet, Stockholm, Sweden

Mostafa Hosseinif Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Hidenori Matsuog National Hospital Organization, Nagasaki Kawatana Medical Center, Nagasaki, Japan

Abbas Mirshafieya Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, IranCorrespondence[email protected] [email protected]

Your download is now in progress and you may close this window